Clinical symptoms in most patients with anti-NMDAR encephalitis coexisting with demyelinating diseases have improved after immunotherapy

Clinical symptoms in most patients with anti-NMDAR encephalitis coexisting with demyelinating diseases have improved after immunotherapy. 1 (HSV-1), West Nile virus (WNV), enteroviruses, and varicella-zoster virus (VZV) [2]. The triggers of the disorder comprise viral infections, tumors, and other unknown factors. It is reported that herpes simplex encephalitis (HSE) plays a vital role in triggering the synthesis of anti-NMDAR antibodies BIX-02565 [3]. In young adult females, the encephalitis is often accompanied with ovarian teratomas [2,4], while males and children are also affected, but the presence of a tumor is uncommon [5,6]. The specific IgG antibodies recognizing the GluN1 subunit of NMDARs result in the receptors’ removal from the synapse through a mechanism of crosslinking and internalization, which is titer-dependent and reversible [4,7,8]. Clinically, after an influenza-like antecedent infection, the patients manifest with obvious behavioral and psychiatric symptoms, which are commonly accompanied by seizures, memory loss, language dysfunctions, dyskinesias, and BIX-02565 impaired consciousness. Additionally, the autonomic instability and hypoventilation are seen in many cases [1,9]. These symptoms are characteristic; however, misdiagnosis and delayed diagnosis occur commonly. A poor outcome, such as persistent and severe neuropsychiatric deficit, may occur in up to 25% of patients [4,5]. Relapses are also observed [10,11]. Despite the complexity and severity of anti-NMDAR encephalitis, full or substantial recovery has been achieved in most patients, who received early diagnosis and prompt multidisciplinary therapy [4]. Here, we aim to review the recent studies on the clinical and laboratory features, diagnosis, and treatments, as well as the mechanisms underlying this disorder. == 2. Epidemiology == It has been reported that anti-NMDAR encephalitis is the most common antibody-associated encephalitis [12]. Since the original description of anti-NMDAR encephalitis [1], there have been many studies on this disorder. A report from Germany indicated that anti-NMDAR encephalitis represented Rabbit polyclonal to CREB1 1% of young individuals (1835 years) hospitalized in the intensive care unit (ICU) [13]. In a multicenter study in Korea, of the 721 patients (aged older than 18 years) with encephalitis of unascertained cause, 40 (6%) were diagnosed with anti-NMDAR encephalitis [14]. A prospective study in England recruited 203 patients with symptoms of encephalitis and showed that of 128 cases whose causes were definite, HSV caused the most cases (36, 28%), while only 9 BIX-02565 (7%) were attributable to anti-NMDAR encephalitis [12]. Another study reported that anti-NMDAR encephalitis was the leading entity, more than 4 times as frequent as HSV-1, WNV, or VZV [2]. The discrepancy may be due to the different population composition, regions, and heterogenic factors. Nevertheless, there has been no study to report the BIX-02565 prevalence rate of the anti-NMDAR encephalitis in a certain region to date. The exact incidence of the disorder is also unknown. In 2005, anti-NMDAR encephalitis was first identified in four young women who suffered from ovarian teratoma and manifested with acute psychiatric symptoms, decreased level of consciousness, seizures, amnesia, and hypoventilation [15]. In the subsequent years, several reports showed that females were significantly more likely to be involved than males. Between September 2007 and February 2011, of the 32 cases who were identified anti-NMDAR encephalitis in the California Encephalitis Project, 75% (24) BIX-02565 were females [2]. In another report including 577 patients, the rate was 81% [11]. In a case-series study containing 51.